Silence Therapeutics Q4 EPS $(0.27) Beats $(0.43) Estimate, Sales $34.000K Miss $6.730M Estimate

Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.43) by 37.21 percent. This is a 200 percent decrease over earnings of $0.27 per share from the same period last year. The company reported quarterly sales of $34.000 thousand which missed the analyst consensus estimate of $6.730 million by 99.49 percent. This is a 99.86 percent decrease over sales of $24.864 million the same period last year.